These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 19120523)

  • 1. Bladder cancer biomarkers and their role in surveillance and screening.
    Van Tilborg AA; Bangma CH; Zwarthoff EC
    Int J Urol; 2009 Jan; 16(1):23-30. PubMed ID: 19120523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A; Kumar R; Gupta NP
    Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bladder cancer biomarkers].
    Dobrowolska-Glazar B; Glazar W; Dobrowolski Z; Lipczyński W
    Przegl Lek; 2010; 67(7):479-83. PubMed ID: 21387760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
    Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
    Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-muscle-invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost-effective alternative?
    de Bekker-Grob EW; van der Aa MN; Zwarthoff EC; Eijkemans MJ; van Rhijn BW; van der Kwast TH; Steyerberg EW
    BJU Int; 2009 Jul; 104(1):41-7. PubMed ID: 19500328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings.
    Bergman J; Reznichek RC; Rajfer J
    BJU Int; 2008 Jan; 101(1):26-9. PubMed ID: 17850364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of tumours of the urinary tract in voided urine.
    Zwarthoff EC
    Scand J Urol Nephrol Suppl; 2008 Sep; (218):147-53. PubMed ID: 18815929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]).
    van der Aa MN; Zwarthoff EC; Steyerberg EW; Boogaard MW; Nijsen Y; van der Keur KA; van Exsel AJ; Kirkels WJ; Bangma C; van der Kwast TH
    Eur Urol; 2009 Mar; 55(3):659-67. PubMed ID: 18501499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of nuclear matrix protein 22 combined with bladder tumor antigen stat test in surveillance of recurring bladder cancer.
    Xu K; Tam PC; Hou S; Wang X; Bai W
    Chin Med J (Engl); 2002 Nov; 115(11):1736-8. PubMed ID: 12609098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. uCyt+ test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma.
    Lodde M; Mian C; Comploj E; Palermo S; Longhi E; Marberger M; Pycha A
    Urology; 2006 May; 67(5):950-4. PubMed ID: 16698355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity.
    Kamat AM; Karam JA; Grossman HB; Kader AK; Munsell M; Dinney CP
    BJU Int; 2011 Oct; 108(7):1119-23. PubMed ID: 21426474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of urinary biomarkers for bladder cancer surveillance: patient perspectives.
    Yossepowitch O; Herr HW; Donat SM
    J Urol; 2007 Apr; 177(4):1277-82; discussion 1282. PubMed ID: 17382711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma.
    Hutterer GC; Karakiewicz PI; Zippe C; Lüdecke G; Boman H; Sanchez-Carbayo M; Casella R; Mian C; Friedrich MG; Eissa S; Akaza H; Serretta V; Hedelin H; Rupesh R; Miyanaga N; Sagalowsky AI; Perrotte P; Lotan Y; Marberger MJ; Shariat SF
    BJU Int; 2008 Mar; 101(5):561-5. PubMed ID: 18257856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma.
    Babjuk M; Soukup V; Pesl M; Kostírová M; Drncová E; Smolová H; Szakacsová M; Getzenberg R; Pavlík I; Dvorácek J
    Urology; 2008 Apr; 71(4):718-22. PubMed ID: 18387400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology.
    Daniely M; Rona R; Kaplan T; Olsfanger S; Elboim L; Freiberger A; Lew S; Leibovitch I
    Cancer; 2007 Dec; 111(6):517-24. PubMed ID: 17963263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer.
    Varella-Garcia M; Akduman B; Sunpaweravong P; Di Maria MV; Crawford ED
    Urol Oncol; 2004; 22(1):16-9. PubMed ID: 14969798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developing biomarkers for improved diagnosis and treatment outcome monitoring of bladder cancer.
    Lintula S; Hotakainen K
    Expert Opin Biol Ther; 2010 Aug; 10(8):1169-80. PubMed ID: 20446896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of molecular and conventional strategies for followup of superficial bladder cancer using decision analysis.
    Nam RK; Redelmeier DA; Spiess PE; Sampson HA; Fradet Y; Jewett MA
    J Urol; 2000 Mar; 163(3):752-7. PubMed ID: 10687970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential of urinary biomarkers in early bladder cancer diagnosis.
    Lam T; Nabi G
    Expert Rev Anticancer Ther; 2007 Aug; 7(8):1105-15. PubMed ID: 18028019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Could nuclear matrix protein 22 (NMP22) play a role with urine cytology in screening for bladder cancer?--experience at Kuwait University.
    Kapila K; Kehinde EO; Anim JT; Mojiminiyi OA; Vinsu A; George SS; Al-Maghrebi M; Al-Mulla F
    Cytopathology; 2008 Dec; 19(6):369-74. PubMed ID: 18631356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.